Genetic Variants in C5 and Poor Response to Eculizumab

2014399 citationsJournal Articlebronze Open Access

Authors

Jun‐ichi Nishimura · Osaka University

Masaki Yamamoto · Osaka University

Shin Hayashi · Tokyo Medical and Dental University

Kazuma Ohyashiki · Tokyo Medical University

Kiyoshi Ando · Tokai University

Andrés Brodsky · University of Buenos Aires

Hideyoshi Noji ·

Abstract

The functional capacity of C5 variants with mutations at Arg885, together with their failure to undergo blockade by eculizumab, account for the poor response to this agent in patients who carry these mutations. (Funded by Alexion Pharmaceuticals and the Ministry of Health, Labor, and Welfare of Japan.).

Topics & Keywords

Complement system in diseases Blood groups and transfusion Coagulation, Bradykinin, Polyphosphates, and Angioedema

UN Sustainable Development Goals

No poverty

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 7, pp. 632-639

DOI: 10.1056/nejmoa1311084

Field-Weighted Citation Impact: 15.32